{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T15:02:48Z","timestamp":1791644568827,"version":"4.3.4"},"reference-count":90,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100004045","name":"Karadeniz Teknik \u00dcniversitesi","doi-asserted-by":"publisher","award":["TTU-2021-9647"],"award-info":[{"award-number":["TTU-2021-9647"]}],"id":[{"id":"10.13039\/501100004045","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Psychiatry Research"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.psychres.2025.116835","type":"journal-article","created":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T05:33:25Z","timestamp":1763444005000},"page":"116835","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["The relationship between serum Interleukin- 6, Interleukin- 18, Interleukin- 2, Eotaxin-1, Monocyte Chemoattractant Protein 1 levels and cognitive functions in treatment-resistant schizophrenia"],"prefix":"10.1016","volume":"355","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2321-1102","authenticated-orcid":false,"given":"I\u015f\u0131lay Manzak","family":"Saka","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filiz Civil","family":"Arslan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1863-6280","authenticated-orcid":false,"given":"Selim","family":"Demir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2036-5317","authenticated-orcid":false,"given":"Ahmet","family":"Mente\u015fe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"JAN","key":"10.1016\/j.psychres.2025.116835_bib0087","article-title":"A systematic review of cognitive function in first-episode psychosis, including a discussion on childhood trauma, stress, and inflammation","volume":"4","author":"Aas","year":"2014","journal-title":"Front. Psychiatry [Internet]"},{"issue":"2","key":"10.1016\/j.psychres.2025.116835_bib0054","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1093\/schbul\/sbaa136","article-title":"High Mobility Group protein 1 and Dickkopf-related protein 1 in schizophrenia and treatment-resistant schizophrenia: associations with interleukin-6, symptom domains, and neurocognitive impairments","volume":"47","author":"Al-Dujaili","year":"2021","journal-title":"Schizophr. Bull. [Internet]"},{"issue":"3","key":"10.1016\/j.psychres.2025.116835_bib0077","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1007\/s12640-019-00112-z","article-title":"The neuroimmune and neurotoxic fingerprint of major neurocognitive psychosis or deficit schizophrenia: a supervised machine learning study","volume":"37","author":"Al-Hakeim","year":"2020","journal-title":"Neurotox. Res. [Internet]"},{"issue":"3","key":"10.1016\/j.psychres.2025.116835_bib0064","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1016\/j.psychres.2015.10.036","article-title":"Does cognitive impairment in treatment-resistant and ultra-treatment-resistant schizophrenia differ from that in treatment responders?","volume":"230","author":"Anderson","year":"2015","journal-title":"Psychiatry Res. [Internet]"},{"issue":"10","key":"10.1016\/j.psychres.2025.116835_bib0084","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1016\/j.jpsychires.2013.05.032","article-title":"Impact of peripheral levels of chemokines, BDNF and oxidative markers on cognition in individuals with schizophrenia","volume":"47","author":"Asevedo","year":"2013","journal-title":"J. Psychiatr Res. [Internet]"},{"key":"10.1016\/j.psychres.2025.116835_bib0020","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.physbeh.2014.02.032","article-title":"Peripheral interleukin-2 level is associated with negative symptoms and cognitive performance in schizophrenia","volume":"129","author":"Asevedo","year":"2014","journal-title":"Physiol. Behav. [Internet]"},{"issue":"4","key":"10.1016\/j.psychres.2025.116835_bib0042","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1080\/14640748608401616","article-title":"Dementia and working memory","volume":"38","author":"Baddeley","year":"1986","journal-title":"Q J. Exp. Psychol. Sect A [Internet]"},{"issue":"6","key":"10.1016\/j.psychres.2025.116835_bib0024","doi-asserted-by":"crossref","first-page":"2264","DOI":"10.1073\/pnas.1211270110","article-title":"CNS-specific immunity at the choroid plexus shifts toward destructive Th2 inflammation in brain aging","volume":"110","author":"Baruch","year":"2013","journal-title":"Proc. Natl. Acad Sci. U S A [Internet]"},{"issue":"11","key":"10.1016\/j.psychres.2025.116835_bib0090","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1016\/j.biopsych.2007.12.007","article-title":"Peripheral inflammation is associated with altered substantia nigra activity and psychomotor slowing in humans","volume":"63","author":"Brydon","year":"2008","journal-title":"Biol. Psychiatry [Internet]"},{"key":"10.1016\/j.psychres.2025.116835_bib0069","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.schres.2023.09.027","article-title":"A systematic review and meta-analysis of the effect of clozapine on cognitive functions in patients with treatment-resistant schizophrenia","volume":"268","author":"Cheuk","year":"2024","journal-title":"Schizophr. Res. [Internet]"},{"issue":"2","key":"10.1016\/j.psychres.2025.116835_bib0008","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.psychres.2013.06.042","article-title":"Differential cognitive performances between schizophrenic responders and non-responders to antipsychotics: correlation with course of the illness, psychopathology, attitude to the treatment and antipsychotics doses","volume":"210","author":"De Bartolomeis","year":"2013","journal-title":"Psychiatry Res."},{"issue":"11","key":"10.1016\/j.psychres.2025.116835_bib0005","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1176\/appi.ajp.2012.12010144","article-title":"Dopamine synthesis capacity in patients with treatment-resistant schizophrenia","volume":"169","author":"Demjaha","year":"2012","journal-title":"Am. J. Psychiatry [Internet]"},{"issue":"11","key":"10.1016\/j.psychres.2025.116835_bib0049","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1017\/S0033291717000435","article-title":"Antipsychotic treatment resistance in first-episode psychosis: prevalence, subtypes and predictors","volume":"47","author":"Demjaha","year":"2017","journal-title":"Psychol. Med. [Internet]"},{"issue":"1\u20133","key":"10.1016\/j.psychres.2025.116835_bib0074","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.schres.2013.10.019","article-title":"Differential correlations between inflammatory cytokines and psychopathology in veterans with schizophrenia: potential role for IL-17 pathway","volume":"151","author":"Dimitrov","year":"2013","journal-title":"Schizophr. Res. [Internet]"},{"issue":"2","key":"10.1016\/j.psychres.2025.116835_bib0040","first-page":"162","article-title":"Theory of mind and selective attention, response inhibition, cognitive flexibility in patients with schizophrenia","volume":"54","author":"E\u015fsizo\u011flu","year":"2017","journal-title":"Noropsikiyatri Ars."},{"issue":"3","key":"10.1016\/j.psychres.2025.116835_bib0007","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1038\/s41386-022-01508-w","article-title":"Anterior cingulate glutamate metabolites as a predictor of antipsychotic response in first episode psychosis: data from the STRATA collaboration","volume":"48","author":"Egerton","year":"2023","journal-title":"Neuropsychopharmacology"},{"issue":"9","key":"10.1016\/j.psychres.2025.116835_bib0089","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1097\/JGP.0b013e31825d08d6","article-title":"Interleukin-6 and memory functions of encoding and recall in healthy and depressed elderly adults","volume":"20","author":"Elderkin-Thompson","year":"2012","journal-title":"Am. J. Geriatr Psychiatry [Internet]"},{"issue":"3","key":"10.1016\/j.psychres.2025.116835_bib0025","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1124\/jpet.114.213074","article-title":"Rapid transport of CCL11 across the blood-brain barrier: regional variation and importance of blood cells","volume":"349","author":"Erickson","year":"2014","journal-title":"J. Pharmacol. Exp. Ther. [Internet]"},{"issue":"6","key":"10.1016\/j.psychres.2025.116835_bib0002","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1093\/schbul\/sbt137","article-title":"Using treatment response to subtype schizophrenia: proposal for a new paradigm in classification","volume":"39","author":"Farooq","year":"2013","journal-title":"Schizophr. Bull. [Internet]"},{"issue":"9","key":"10.1016\/j.psychres.2025.116835_bib0033","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/j.tins.2005.06.008","article-title":"IL-18: a key player in neuroinflammation and neurodegeneration?","volume":"28","author":"Felderhoff-Mueser","year":"2005","journal-title":"Trends Neurosci. [Internet]"},{"issue":"8","key":"10.1016\/j.psychres.2025.116835_bib0022","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1038\/mp.2015.90","article-title":"Elevated peripheral cytokines characterize a subgroup of people with schizophrenia displaying poor verbal fluency and reduced Broca\u2019s area volume","volume":"21","author":"Fillman","year":"2016","journal-title":"Mol. Psychiatry"},{"issue":"6","key":"10.1016\/j.psychres.2025.116835_bib0053","first-page":"449","article-title":"Interleukin-6: the missing element of the neurocognitive deterioration in schizophrenia? The focus on genetic underpinnings, cognitive impairment and clinical manifestation","volume":"265","author":"Frydecka","year":"2015","journal-title":"Eur. Arch. Psychiatry Clin. Neurosci. [Internet]"},{"key":"10.1016\/j.psychres.2025.116835_bib0003","unstructured":"Gilbert E., M\u00e9rette C., Jomphe V., Rouleau N., Bouchard R.-.H., Roy M.-.A., et al. Cluster analysis of cognitive deficits may mark heterogeneity in schizophrenia in terms of outcome and response to treatment, 2020."},{"issue":"1","key":"10.1016\/j.psychres.2025.116835_bib0004","first-page":"1","article-title":"Is treatment-resistant schizophrenia categorically distinct from treatment-responsive schizophrenia? A systematic review","volume":"17","author":"Gillespie","year":"2017","journal-title":"BMC Psychiatry [Internet]"},{"issue":"1","key":"10.1016\/j.psychres.2025.116835_bib0055","article-title":"Inflammatory markers are associated with psychomotor slowing in patients with schizophrenia compared to healthy controls","volume":"6","author":"Goldsmith","year":"2020","journal-title":"NPJ Schizophr. [Internet]"},{"key":"10.1016\/j.psychres.2025.116835_bib0076","article-title":"Predicting real-world functioning in outpatients with schizophrenia: role of inflammation and psychopathology","volume":"280","author":"Gonzalez-Blanco","year":"2019","journal-title":"Psychiatry Res. [Internet]"},{"issue":"4","key":"10.1016\/j.psychres.2025.116835_bib0032","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1016\/j.neuroscience.2009.05.048","article-title":"Long term exposure to the chemokine CCL2 activates the nigrostriatal dopamine system: a novel mechanism for the control of dopamine release","volume":"162","author":"Guyon","year":"2009","journal-title":"Neuroscience"},{"issue":"1\u20133","key":"10.1016\/j.psychres.2025.116835_bib0068","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.schres.2007.11.014","article-title":"A randomized double-blind comparison of ziprasidone vs. clozapine for cognition in patients with schizophrenia selected for resistance or intolerance to previous treatment","volume":"105","author":"Harvey","year":"2008","journal-title":"Schizophr. Res."},{"issue":"1","key":"10.1016\/j.psychres.2025.116835_bib0011","first-page":"1","article-title":"Multiple serum anti-glutamate receptor antibody levels in clozapine-treated\/na\u00efve patients with treatment-resistant schizophrenia","volume":"24","author":"He","year":"2024","journal-title":"BMC Psychiatry [Internet]"},{"issue":"1","key":"10.1016\/j.psychres.2025.116835_bib0031","first-page":"1","article-title":"CCL2\/MCP-1 modulation of microglial activation and proliferation","volume":"8","author":"Hinojosa","year":"2011","journal-title":"J. Neuroinflammation [Internet]"},{"key":"10.1016\/j.psychres.2025.116835_bib0078","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.schres.2016.09.019","article-title":"Abnormalities in chemokine levels in schizophrenia and their clinical correlates","volume":"181","author":"Hong","year":"2017","journal-title":"Schizophr. Res. [Internet]"},{"issue":"3","key":"10.1016\/j.psychres.2025.116835_bib0038","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1176\/appi.ajp.2016.16050503","article-title":"Treatment-resistant schizophrenia: treatment response and resistance in psychosis (TRRIP) working group consensus guidelines on diagnosis and terminology","volume":"174","author":"Howes","year":"2017","journal-title":"Am. J. Psychiatry [Internet]"},{"issue":"7","key":"10.1016\/j.psychres.2025.116835_bib0010","doi-asserted-by":"crossref","first-page":"3220","DOI":"10.1017\/S003329172100533X","article-title":"Altered glutamate level and its association with working memory among patients with treatment-resistant schizophrenia (TRS): a proton magnetic resonance spectroscopy study","volume":"53","author":"Huang","year":"2023","journal-title":"Psychol. Med."},{"key":"10.1016\/j.psychres.2025.116835_bib0062","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.pnpbp.2015.08.010","article-title":"Treatment resistant schizophrenia is associated with the worst community functioning among severely-ill highly-disabling psychiatric conditions and is the most relevant predictor of poorer achievements in functional milestones","volume":"65","author":"Iasevoli","year":"2016","journal-title":"Prog. Neuro-Psychopharmacology Biol. Psychiatry"},{"issue":"October","key":"10.1016\/j.psychres.2025.116835_bib0018","first-page":"1","article-title":"Peripheral biomarkers of treatment-resistant schizophrenia: genetic, inflammation and stress perspectives","volume":"13","author":"Jiao","year":"2022","journal-title":"Front. Pharmacol."},{"issue":"3","key":"10.1016\/j.psychres.2025.116835_bib0061","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/S0920-9964(01)00279-1","article-title":"Neuropsychological impairments in neuroleptic-responder vs. -nonresponder schizophrenic patients and healthy volunteers","volume":"53","author":"Joober","year":"2002","journal-title":"Schizophr. Res."},{"issue":"2","key":"10.1016\/j.psychres.2025.116835_bib0001","doi-asserted-by":"crossref","DOI":"10.4088\/JCP.18com12123","article-title":"Clinical guidance on the identification and management of treatment-resistant schizophrenia","volume":"80","author":"Kane","year":"2019","journal-title":"J. Clin. Psychiatry"},{"issue":"5","key":"10.1016\/j.psychres.2025.116835_bib0073","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/S2215-0366(15)00098-X","article-title":"D-serine for the treatment of negative symptoms in individuals at clinical high risk of schizophrenia: a pilot, double-blind, placebo-controlled, randomised parallel group mechanistic proof-of-concept trial","volume":"2","author":"Kantrowitz","year":"2015","journal-title":"The lancet Psychiatry [Internet]"},{"issue":"2","key":"10.1016\/j.psychres.2025.116835_bib0039","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1093\/schbul\/13.2.261","article-title":"The positive and negative syndrome scale (PANSS) for schizophrenia","volume":"13","author":"Kay","year":"1987","journal-title":"Schizophr. Bull. [Internet]"},{"key":"10.1016\/j.psychres.2025.116835_bib0083","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.jpsychires.2021.04.007","article-title":"Chemokine MCP1 is associated with cognitive flexibility in schizophrenia: a preliminary analysis","volume":"138","author":"Klaus","year":"2021","journal-title":"J. Psychiatr Res. [Internet]"},{"issue":"5","key":"10.1016\/j.psychres.2025.116835_bib0091","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/j.bbi.2005.04.010","article-title":"Low-dose endotoxemia and human neuropsychological functions","volume":"19","author":"Krabbe","year":"2005","journal-title":"Brain Behav. Immun [Internet]"},{"issue":"12","key":"10.1016\/j.psychres.2025.116835_bib0060","doi-asserted-by":"crossref","first-page":"2100","DOI":"10.1017\/S0033291718002957","article-title":"Neuropsychological function at first episode in treatment-resistant psychosis: findings from the \u00c6SOP-10 study","volume":"49","author":"Kravariti","year":"2019","journal-title":"Psychol. Med. [Internet]"},{"issue":"4","key":"10.1016\/j.psychres.2025.116835_bib0035","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1111\/bph.13364","article-title":"Microglial activation and progressive brain changes in schizophrenia","volume":"173","author":"Laskaris","year":"2016","journal-title":"Br. J. Pharmacol. [Internet]"},{"issue":"5","key":"10.1016\/j.psychres.2025.116835_bib0045","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1176\/ajp.151.5.675","article-title":"\u201cJust right\u201d perceptions associated with compulsive behavior in Tourette\u2019s syndrome","volume":"151","author":"Leckman","year":"1994","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.psychres.2025.116835_bib0043","doi-asserted-by":"crossref","unstructured":"Lehto J. Are executive function tests dependent on working memory capacity?, 101080\/713755616 [Internet]. 2018 Jan 1 [cited 2022 Aug 4];49(1):29\u201350. Available from: https:\/\/journals.sagepub.com\/doi\/10.1080\/713755616.","DOI":"10.1080\/027249896392793"},{"key":"10.1016\/j.psychres.2025.116835_bib0047","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1007\/s00415-005-0003-0","article-title":"Neuropsychological Assessment, fourth edition","volume":"252","author":"Lezak","year":"2005","journal-title":"J. Neurol."},{"issue":"5","key":"10.1016\/j.psychres.2025.116835_bib0059","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1007\/s00406-024-01885-x","article-title":"Immunoinflammatory features and cognitive function in treatment-resistant schizophrenia: unraveling distinct patterns in clozapine-resistant patients","volume":"275","author":"Li","year":"2025","journal-title":"Eur. Arch. Psychiatry Clin. Neurosci."},{"issue":"1","key":"10.1016\/j.psychres.2025.116835_bib0016","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/S0920-9964(98)00034-6","article-title":"The inflammatory response system in treatment-resistant schizophrenia: increased serum interleukin-6","volume":"32","author":"Lin","year":"1998","journal-title":"Schizophr. Res."},{"issue":"1","key":"10.1016\/j.psychres.2025.116835_bib0012","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12888-019-2204-6","article-title":"Severity in sustained attention impairment and clozapine-resistant schizophrenia: a retrospective study","volume":"19","author":"Lin","year":"2019","journal-title":"BMC. Psychiatry"},{"key":"10.1016\/j.psychres.2025.116835_bib0072","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.comppsych.2019.01.003","article-title":"Changes in serum TNF-\u03b1, IL-18, and IL-6 concentrations in patients with chronic schizophrenia at admission and at discharge","volume":"90","author":"Luo","year":"2019","journal-title":"Compr. Psychiatry [Internet]"},{"key":"10.1016\/j.psychres.2025.116835_bib0080","article-title":"A pilot study of biomarkers of oxidative stress in serum and schizophrenia","volume":"284","author":"Ma","year":"2020","journal-title":"Psychiatry Res. [Internet]"},{"issue":"2","key":"10.1016\/j.psychres.2025.116835_bib0044","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1037\/0033-2909.109.2.163","article-title":"Half a century of reseach on the stroop effect: an integrative review","volume":"109","author":"MacLeod","year":"1991","journal-title":"Psychol. Bull."},{"issue":"2","key":"10.1016\/j.psychres.2025.116835_bib0026","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1007\/s12640-019-00054-6","article-title":"Breakdown of the paracellular tight and adherens junctions in the gut and blood brain barrier and damage to the vascular barrier in patients with deficit schizophrenia","volume":"36","author":"Maes","year":"2019","journal-title":"Neurotox. Res. [Internet]"},{"issue":"6","key":"10.1016\/j.psychres.2025.116835_bib0088","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1097\/01.psy.0000238451.22174.92","article-title":"Interleukin-6 covaries inversely with cognitive performance among middle-aged community volunteers","volume":"68","author":"Marsland","year":"2006","journal-title":"Psychosom. Med. [Internet]"},{"issue":"1\u20133","key":"10.1016\/j.psychres.2025.116835_bib0056","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.schres.2012.03.004","article-title":"Cognitive impairment is related to oxidative stress and chemokine levels in first psychotic episodes","volume":"137","author":"Mart\u00ednez-Cengotitabengoa","year":"2012","journal-title":"Schizophr. Res. [Internet]"},{"issue":"2","key":"10.1016\/j.psychres.2025.116835_bib0066","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1093\/oxfordjournals.schbul.a033376","article-title":"The effects of clozapine, risperidone, and olanzapine on cognitive function in schizophrenia","volume":"25","author":"Meltzer","year":"1999","journal-title":"Schizophr. Bull. [Internet]"},{"key":"10.1016\/j.psychres.2025.116835_bib0050","doi-asserted-by":"crossref","unstructured":"Meltzer H.Y. Treatment-resistant schizophrenia - the role of Clozapine. 101185\/03007999709113338 [Internet]. 2008 [cited 2022 Apr 19];14(1):1\u201320. Available from: https:\/\/www.tandfonline.com\/doi\/abs\/10.1185\/03007999709113338.","DOI":"10.1185\/03007999709113338"},{"issue":"4","key":"10.1016\/j.psychres.2025.116835_bib0023","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1007\/s00406-020-01134-x","article-title":"Inflammation, hippocampal volume, and cognition in schizophrenia: results from the Northern Finland Birth Cohort 1966","volume":"271","author":"Miller","year":"2021","journal-title":"Eur. Arch. Psychiatry Clin. Neurosci. [Internet]"},{"key":"10.1016\/j.psychres.2025.116835_bib0086","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.schres.2017.04.015","article-title":"Cytokines and C-reactive protein alterations with respect to cognitive impairment in schizophrenia and bipolar disorder: a systematic review","volume":"192","author":"Misiak","year":"2018","journal-title":"Schizophr. Res."},{"issue":"5","key":"10.1016\/j.psychres.2025.116835_bib0058","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1093\/schbul\/sbv028","article-title":"Cortisol and inflammatory biomarkers predict poor treatment response in first episode psychosis","volume":"41","author":"Mondelli","year":"2015","journal-title":"Schizophr. Bull. [Internet]"},{"issue":"1","key":"10.1016\/j.psychres.2025.116835_bib0034","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1006\/viro.2001.1029","article-title":"Impaired microglial activation in the brain of IL-18-gene-disrupted mice after neurovirulent Influenza A virus infection","volume":"287","author":"Mori","year":"2001","journal-title":"Virology"},{"issue":"1","key":"10.1016\/j.psychres.2025.116835_bib0048","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/S0165-1781(00)00241-9","article-title":"An analysis of the specificity and the syndromal correlates of verbal memory impairments in schizophrenia","volume":"101","author":"Moritz","year":"2001","journal-title":"Psychiatry Res."},{"issue":"3","key":"10.1016\/j.psychres.2025.116835_bib0006","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1093\/schbul\/sbv151","article-title":"Treatment-resistant schizophrenia patients show elevated anterior cingulate cortex glutamate compared to Treatment-responsive","volume":"42","author":"Mouchlianitis","year":"2016","journal-title":"Schizophr. Bull. [Internet]"},{"issue":"6","key":"10.1016\/j.psychres.2025.116835_bib0015","doi-asserted-by":"crossref","first-page":"422","DOI":"10.3109\/15622975.2015.1062552","article-title":"High predictive value of immune-inflammatory biomarkers for schizophrenia diagnosis and association with treatment resistance","volume":"16","author":"Noto","year":"2015","journal-title":"World J. Biol. Psychiatry [Internet]"},{"key":"10.1016\/j.psychres.2025.116835_bib0082","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/j.schres.2017.09.016","article-title":"First-episode psychosis patients display increased plasma IL-18 that correlates with cognitive dysfunction","volume":"195","author":"Orhan","year":"2018","journal-title":"Schizophr. Res. [Internet]"},{"issue":"12","key":"10.1016\/j.psychres.2025.116835_bib0028","doi-asserted-by":"crossref","first-page":"2274","DOI":"10.1002\/glia.22892","article-title":"CCL11 enhances excitotoxic neuronal death by producing reactive oxygen species in microglia","volume":"63","author":"Parajuli","year":"2015","journal-title":"Glia. [Internet]"},{"key":"10.1016\/j.psychres.2025.116835_bib0036","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1007\/978-1-62703-071-7_15","article-title":"Interleukin-2 and the brain: dissecting central versus peripheral contributions using unique mouse models","volume":"934","author":"Petitto","year":"2012","journal-title":"Methods Mol Biol [Internet]"},{"key":"10.1016\/j.psychres.2025.116835_bib0037","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1007\/978-1-61779-458-2_27","article-title":"Interleukin-2 and the septohippocampal system: intrinsic actions and autoimmune processes relevant to neuropsychiatric disorders","volume":"829","author":"Petitto","year":"2012","journal-title":"Methods Mol. Biol. [Internet]"},{"key":"10.1016\/j.psychres.2025.116835_bib0017","doi-asserted-by":"crossref","DOI":"10.1016\/j.nsa.2024.104059","article-title":"Biomarkers of treatment-resistant schizophrenia: a systematic review","volume":"3","author":"Pisanu","year":"2024","journal-title":"Neurosci. Appl."},{"key":"10.1016\/j.psychres.2025.116835_bib0030","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.pneurobio.2013.02.001","article-title":"Current status of chemokines in the adult CNS","volume":"104","author":"R\u00e9aux-Le Goazigo","year":"2013","journal-title":"Prog. Neurobiol. [Internet]"},{"issue":"S1","key":"10.1016\/j.psychres.2025.116835_bib0014","article-title":"Cognition in treatment resistant versus non- treatment resistant schizophrenia","volume":"68","author":"Shah","year":"2025","journal-title":"Eur. Psychiatry [Internet]"},{"issue":"1","key":"10.1016\/j.psychres.2025.116835_bib0085","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1007\/s12640-018-9937-8","volume":"35","author":"Sirivichayakul","year":"2019","journal-title":"Neurotox. Res. [Internet]."},{"key":"10.1016\/j.psychres.2025.116835_bib0065","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/j.jpsychires.2021.07.019","article-title":"Longitudinal course of cognition in schizophrenia: does treatment resistance play a role?","volume":"141","author":"Spangaro","year":"2021","journal-title":"J. Psychiatr. Res."},{"issue":"3","key":"10.1016\/j.psychres.2025.116835_bib0063","doi-asserted-by":"crossref","first-page":"139","DOI":"10.4103\/0019-5545.55936","article-title":"Cognitive dysfunction and associated factors in patients with chronic schizophrenia","volume":"47","author":"Srinivasan","year":"2005","journal-title":"Indian J. Psychiatry [Internet]"},{"key":"10.1016\/j.psychres.2025.116835_bib0029","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.neubiorev.2014.02.001","article-title":"Chemokines and chemokine receptors in mood disorders, schizophrenia, and cognitive impairment: a systematic review of biomarker studies","volume":"42","author":"Stuart","year":"2014","journal-title":"Neurosci. Biobehav. Rev. [Internet]"},{"issue":"2","key":"10.1016\/j.psychres.2025.116835_bib0041","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/0165-1781(93)90019-D","article-title":"Factors of the Wisconsin card sorting Test as measures of frontal-lobe function in schizophrenia and in chronic alcoholism","volume":"46","author":"Sullivan","year":"1993","journal-title":"Psychiatry Res."},{"issue":"10","key":"10.1016\/j.psychres.2025.116835_bib0009","doi-asserted-by":"crossref","first-page":"552","DOI":"10.4103\/singaporemedj.SMJ-2024-143","article-title":"Association between treatment resistance and cognitive function in schizophrenia","volume":"65","author":"Sun","year":"2024","journal-title":"Singapore Med. J."},{"issue":"4","key":"10.1016\/j.psychres.2025.116835_bib0057","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1111\/eip.13031","article-title":"Elevated levels of IL-18 associated with schizophrenia and first episode psychosis: a systematic review and meta-analysis","volume":"15","author":"Syed","year":"2021","journal-title":"Early. Interv. Psychiatry"},{"issue":"January","key":"10.1016\/j.psychres.2025.116835_bib0013","article-title":"Cortico-cognition coupling in treatment resistant schizophrenia","volume":"35","author":"Syeda","year":"2022","journal-title":"Neuroimage Clin."},{"issue":"3","key":"10.1016\/j.psychres.2025.116835_bib0046","first-page":"189","article-title":"Elmasta\u015f Dike\u00e7 B. A study to determine the norms for the trail making test for the age range of 20-49 in Turkey","volume":"26","author":"T\u00fcrke\u015f","year":"2015","journal-title":"Turk. Psikiyatr Derg."},{"issue":"1\u20133","key":"10.1016\/j.psychres.2025.116835_bib0019","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.schres.2015.10.038","article-title":"Increased interleukin-2 serum levels were associated with psychopathological symptoms and cognitive deficits in treatment-resistant schizophrenia","volume":"169","author":"Tan","year":"2015","journal-title":"Schizophr. Res. [Internet]"},{"issue":"3","key":"10.1016\/j.psychres.2025.116835_bib0079","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1016\/j.pnpbp.2007.11.019","article-title":"Increased serum levels of CCL11\/eotaxin in schizophrenia","volume":"32","author":"Teixeira","year":"2008","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry [Internet]"},{"issue":"7362","key":"10.1016\/j.psychres.2025.116835_bib0027","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1038\/nature10357","article-title":"The ageing systemic milieu negatively regulates neurogenesis and cognitive function","volume":"477","author":"Villeda","year":"2011","journal-title":"Nat"},{"issue":"3","key":"10.1016\/j.psychres.2025.116835_bib0067","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1017\/S146114570500516X","article-title":"A meta-analysis of neuropsychological change to clozapine, olanzapine, quetiapine, and risperidone in schizophrenia","volume":"8","author":"Woodward","year":"2005","journal-title":"Int. J. Neuropsychopharmacol. [Internet]"},{"key":"10.1016\/j.psychres.2025.116835_bib0021","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.jpsychires.2016.01.013","article-title":"Altered interleukin-18 levels are associated with cognitive impairment in chronic schizophrenia","volume":"76","author":"Wu","year":"2016","journal-title":"J. Psychiatr. Res. [Internet]"},{"issue":"8","key":"10.1016\/j.psychres.2025.116835_bib0070","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1016\/j.jpsychires.2012.04.026","article-title":"Elevated interleukin-18 serum levels in chronic schizophrenia: association with psychopathology","volume":"46","author":"Xiu","year":"2012","journal-title":"J. Psychiatr Res. [Internet]"},{"issue":"8","key":"10.1016\/j.psychres.2025.116835_bib0052","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1038\/sj.npp.1300756","article-title":"Cortisol and cytokines in chronic and treatment-resistant patients with schizophrenia: association with psychopathology and response to antipsychotics","volume":"30","author":"Zhang","year":"2005","journal-title":"Neuropsychopharmacol"},{"key":"10.1016\/j.psychres.2025.116835_bib0081","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.bbi.2013.03.001","article-title":"Interleukin 18 and cognitive impairment in first episode and drug na\u00efve schizophrenia versus healthy controls","volume":"32","author":"Zhang","year":"2013","journal-title":"Brain Behav. Immun. [Internet]"},{"key":"10.1016\/j.psychres.2025.116835_bib0071","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.psyneuen.2016.03.002","article-title":"Serum IL-18 level, clinical symptoms and IL-18-607A\/C polymorphism among chronic patients with schizophrenia in a Chinese Han population","volume":"68","author":"Zhang","year":"2016","journal-title":"Psychoneuroendocrinology [Internet]"},{"key":"10.1016\/j.psychres.2025.116835_bib0075","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.bbi.2015.09.014","article-title":"Interaction of BDNF with cytokines in chronic schizophrenia","volume":"51","author":"Zhang","year":"2016","journal-title":"Brain Behav. Immun. [Internet]"}],"container-title":["Psychiatry Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165178125004809?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165178125004809?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T08:50:20Z","timestamp":1781167820000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0165178125004809"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":90,"alternative-id":["S0165178125004809"],"URL":"https:\/\/doi.org\/10.1016\/j.psychres.2025.116835","relation":{},"ISSN":["0165-1781"],"issn-type":[{"value":"0165-1781","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The relationship between serum Interleukin- 6, Interleukin- 18, Interleukin- 2, Eotaxin-1, Monocyte Chemoattractant Protein 1 levels and cognitive functions in treatment-resistant schizophrenia","name":"articletitle","label":"Article Title"},{"value":"Psychiatry Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.psychres.2025.116835","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"116835"}}